Compass PathwaysMEX:CMPSN 14 EBITDA Margin % is 0.00% as of Mar. 2026. GuruFocus rates MEX:CMPSN with a GF Score™ of 14/100. The stock has 2 warning signs investors should review. Among 668 Healthcare Providers & Services companies, Compass Pathways ranks worse than 149700.45% on this metric.
EBITDA Margin % is calculated as EBITDA divided by its Revenue. Compass Pathways's EBITDA for the
three
months ended in Mar. 2026 was MXN1,670.84 Mil. Compass Pathways's Revenue for the
three
months ended in Mar. 2026 was MXN0.00 Mil. Therefore, Compass Pathways's EBITDA margin for the quarter that ended in Mar. 2026 was 0.00%.
EBITDA Margin % is the ratio of EBITDA divided by net sales or Revenue. It is an performance metric measuring company's operating profitability. EBITDA Margin takes depreciation and amortization, interest expense and tax into account, which makes it easy to compare the relative profitability of companies of different sizes in the same industry.
Compass Pathways EBITDA Margin % Related Terms
Compass Pathways EBITDA Margin % Historical Data
* Premium members only.
The historical data trend for Compass Pathways's EBITDA Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
MEX:CMPSN vs MD, SGRY, ADUS: EBITDA Margin % Comparison
For the Medical Care Facilities subindustry, Compass Pathways's EBITDA Margin %, along with its competitors' market caps and EBITDA Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Compass Pathways EBITDA Margin % vs Healthcare Providers & Services Industry
For the Healthcare Providers & Services industry and Healthcare sector, Compass Pathways's EBITDA Margin % distribution charts can be found below:
* The bar in red indicates where Compass Pathways's EBITDA Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Compass Pathways (MEX:CMPSN) has a EBITDA Margin % of 0.00% as of Mar. 2026. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Compass Pathways and its competitors. According to the industry distribution chart, Compass Pathways ranks #999999 out of 668 companies in the Healthcare Providers & Services industry.
Is Compass Pathways' EBITDA Margin % too high?
Compass Pathways' current EBITDA Margin % is 0.00%. Based on the distribution chart, Compass Pathways ranks #999999 out of 668 companies in the Healthcare Providers & Services industry, which is in the bottom quartile relative to peers. Overall, Compass Pathways has a GF Score™ of 14/100, reflecting its overall financial health beyond just this single metric.
How does Compass Pathways' EBITDA Margin % compare to MD and SGRY?
According to the Healthcare Providers & Services industry distribution chart, Compass Pathways ranks #999999 out of 668 companies for EBITDA Margin %. This places Compass Pathways in the lower half of its industry. The industry median EBITDA Margin % is 10.21. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBITDA Margin % for a Healthcare Providers & Services company?
The median EBITDA Margin % among Healthcare Providers & Services companies is 10.21, based on 668 companies in the industry. Companies in the top quartile (top 25%) have a EBITDA Margin % significantly above this median, while those in the bottom quartile fall well below. However, EBITDA Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBITDA Margin % mean?
A high EBITDA Margin % can signal that a stock is expensive relative to its fundamentals. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Compass Pathways and its competitors. For the Healthcare Providers & Services industry, the median EBITDA Margin % is 10.21 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Compass Pathways's current EBITDA Margin % is 0.00%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Compass Pathways stock overvalued right now?
Compass Pathways (MEX:CMPSN) has a current EBITDA Margin % of 0.00%. The current EBITDA Margin % is 0.00%. Compass Pathways' overall GF Score™ is 14/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBITDA Margin % calculated?
EBITDA Margin % is calculated from a company's financial statements. For Compass Pathways (MEX:CMPSN), the current EBITDA Margin % is 0.00% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Compass Pathways PLC is a biotechnology company focused on developing therapies for mental health conditions. Its research centers on a proprietary synthetic psilocybin formulation, COMP360, which is administered alongside psychological support. The company is conducting clinical trials to evaluate the safety and efficacy of this treatment in patients with treatment-resistant depression and other mental health disorders. The company operates in one operating segment.
14GF Score
Get the complete analysis for MEX:CMPSN
EBITDA Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
MEX:CMPSN has been successfully added to your 
